Shockwave completes enrolment in study of coronary intravascular lithotripsy

Shockwave Medical has completed enrolment in its US Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study—DISRUPT CAD III—for the use of intravascular lithotripsy (IVL) for the management of heavily calcified coronary arteries. A press release reports that the investigational Shockwave IVL system with the Shockwave C2 Coronary IVL catheter, which has been [...]

2020-04-08T16:04:21+00:00April 8th, 2020|Tags: , , |

Shockwave launch DISRUPT CAD IV study to support Japanese device approval

Shockwave Lithotripsy Shockwave Medical has announced that it has initiated the DISRUPT CAD IV study of is intravascular lithotripsy (IVL) system for the management of in heavily calcified coronary arteries, with the intention of using data from the study to supporting regulatory device approval in Japan. Shigeru Saito (Shonan Kamakura General Hospital, [...]

2019-11-11T15:15:29+00:00November 11th, 2019|Tags: , , |
Go to Top